查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1871935

全球个人化微生物组疗法市场预测（至2032年）－按疗法类型、给药途径、技术、应用、最终用户和地区分類的分析

Personalized Microbiome Therapeutics Market Forecasts to 2032 - Global Analysis By Therapy Type, Route of Administration, Technology, Application, End User, and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，全球个人化微生物组疗法市场预计到 2025 年价值 2.5 亿美元，到 2032 年达到 10.5 亿美元，在预测期内以 22.7% 的复合年增长率增长。

个人化微生物组治疗方法是根据个体独特的微生物组特征，客製化地调节其肠道、皮肤或其他部位的微生物组。透过分析微生物组的组成和功能，可以利用益生菌、益生元、合益素或微生物群落来调整治疗方法，进而恢復菌丛平衡、预防疾病并改善健康。这种精准的方法利用了微生物组科学、基因组学和人工智慧领域的最新进展，能够针对消化器官系统、免疫系统、代谢系统和神经系统疾病进行标靶干预。

根据 CellPress 报道，这些公司正在开发客製化益生菌复合物，旨在与个人的肠道菌群相匹配，他们声称这种复合物可以比频谱替代疗法更有效地治疗发炎性肠道疾病 (IBD) 等疾病。

人们对肠道健康疗法的兴趣日益浓厚

随着消费者对维护消化系统健康和预防慢性疾病的关注度日益提高，全球对肠道健康疗法的需求正在飙升。在精准医疗日益发展的趋势下，个人化微生物组疗法正受到越来越多的关注，精准医疗强调透过调节微生物组来治疗代谢性疾病、神经系统疾病和自体免疫疾病。越来越多的科学证据显示肠-脑轴和肠-免疫轴的存在，这进一步加速了该疗法的应用。此外，不断扩展的临床试验计画以及生物技术新兴企业与大型製药公司之间的合作也推动了这一成长。这一趋势使微生物组疗法成为医疗保健领域变革性的前沿领域。

复杂的监管核准流程

由于生物治疗产品和基因介入药物的法规结构十分严格，市场面临许多障碍。基于微生物组的药物核准流程在不同地区仍不明确，导致商业化进程延缓。不同监管机构（例如FDA和EMA）在安全性和有效性标准上的差异，进一步加剧了复杂性。此外，缺乏临床证据和标准化的生产通讯协定也阻碍了研发进展。这些障碍推高了研发成本，延长了产品上市时间，限制了市场扩充性，儘管该领域具有强大的创新潜力。

微生物基因定序技术的进步

次世代定序技术使研究人员能够以前所未有的精确度解读个体微生物组。这项技术进步使得针对患者微生物谱量身定制的精准标靶治疗方案成为可能。人工智慧和生物资讯学的日益融合正在增强微生物行为的预测模型。此外，定序成本的下降扩大了临床研究和诊断的覆盖范围。这些进展为个人化治疗模式铺平了道路，拓宽了微生物组调节疗法的临床应用。

长期疗效数据尚不确定

儘管早期临床试验显示出令人鼓舞的结果，但有限的纵向研究对基于微生物组的疗法的持续疗效提出了质疑。宿主反应和微生物组稳定性的差异引发了人们对疗效可重复性和一致性的担忧。此外，缺乏明确的治疗成功生物标记也使治疗后评估变得复杂。随着其他治疗方法的不断发展，对疗效持续性的质疑可能会阻碍其广泛应用。在获得可靠的多年疗效数据以支持临床可信度和市场永续性之前，投资者和医疗服务提供者仍将保持谨慎。

新冠疫情的影响：

新冠疫情凸显了免疫力与肠道环境之间的联繫，并加速了透过调节肠道菌丛来增强免疫力的研究。然而，封锁措施扰乱了临床试验和微生物培养供应链。疫情后的恢復期重新燃起了人们对益生菌和以肠道菌丛标靶治疗的兴趣。大众对个人化医疗解决方案的认知度提高，也促进了临床合作。因此，新冠疫情既是暂时的干扰因素，也是推动以肠道菌丛为中心的创新发展的催化剂。

预计在预测期内，生物治疗产品领域将占据最大的市场份额。

由于生物製剂能够直接调节宿主微生物群，并在治疗復发性困难梭状芽孢桿菌传染病、发炎性肠道疾病和代谢紊乱方面展现出显着疗效，预计在预测期内，生物製剂将占据最大的市场份额。 VOWST 和 REBYOTA 等产品的监管核准进一步佐证了该领域的有效性。生物製剂能够恢復微生物平衡并发挥标靶作用，使其成为个人化医疗应用的理想选择。不断增长的临床应用、日益扩大的适应症以及强大的研发管线，已使生物製药成为市场的基础性组成部分。

预计在预测期内，直肠和灌肠给药途径将呈现最高的复合年增长率。

由于直肠和灌肠给药途径在局部肠道菌群重建方面具有卓越的疗效，预计在预测期内，该途径将实现最高的成长率。这种给药途径避免了胃酸降解，确保了活性微生物的高存活率。它尤其适用于治疗溃疡性大肠炎和復发性困难梭状芽孢桿菌传染病等下消化道疾病。製剂技术的创新和患者友善装置的出现正在提高其接受度。随着临床证据的积累，直肠给药作为​​一种精准靶向的微生物组疗法，因其起效迅速且全身暴露量极低而日益受到认可。

占比最大的地区：

由于胃肠道疾病盛行率不断上升以及人们对预防性医疗保健的日益关注，亚太地区预计将在预测期内占据最大的市场份额。中国、日本和印度等国家正在加大对微生物组研究和个人化医疗的投入。不断完善的医疗基础设施、有利的监管改革以及消费者对肠道健康日益增长的意识正在推动相关技术的普及。在地化生产能力和策略合作伙伴关係将进一步增强市场渗透率，使亚太地区成为关键的成长区域。

复合年增长率最高的地区：

在预测期内，北美预计将实现最高的复合年增长率，这主要得益于先进的研发、完善的临床试验基础设施以及早期监管核准。美国在微生物组领域拥有丰富的研发管线、学术合作和创业投资，引领创新。对个人化治疗日益增长的需求、与数位健康平台的整合以及有利的报销政策正在加速该领域的应用。策略性收购以及VOWST和REBYOTA等获得FDA核准的产品正在增强市场势头，使北美成为微生物组疗法的创新中心。

免费客製化服务：

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
  • 分析材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球个人化微生物组疗法市场（依疗法类型划分）

  • 活体生物製药
  • 粪便微生物移植（FMT）
  • 人工益生菌
  • 基于噬菌体的治疗方法
  • 后生元製剂
  • 合益素组合

6. 全球个人化微生物组疗法市场（依给药途径划分）

  • 口服胶囊
  • 直肠/灌肠给药
  • 鼻腔和吸力系统
  • 注射剂型
  • 经皮给药
  • 封装微生物凝胶

7. 全球个人化微生物组疗法市场（依技术划分）

  • 总体基因体学定序
  • 人工智慧驱动的微生物组图谱绘製
  • CRISPR基因编辑
  • 单细胞分析
  • 多体学整合
  • 机器学习治疗设计

8. 全球个人化微生物组疗法市场（按应用划分）

  • 胃肠道疾病
  • 代谢性疾病
  • 神经系统疾病
  • 免疫相关疾病
  • 癌症免疫疗法支持
  • 心血管健康

9. 全球个人化微生物组疗法市场（依最终用户划分）

  • 医院和诊所
  • 製药公司
  • 实验室
  • 生技Start-Ups
  • CMO（合约生产组织）
  • 学术机构

10. 全球个人化微生物组疗法市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十二章：公司简介

  • Seres Therapeutics
  • Finch Therapeutics
  • Ferring Pharmaceuticals
  • Rebiotix
  • Synlogic
  • 4D Pharma
  • Enterome
  • Bacthera
  • Vedanta Biosciences
  • Astellas
  • BioMe
  • Nestle Health Science
  • Takeda
  • Pfizer
  • Evelo Biosciences
  • Kirin Holdings
  • GSK
Product Code: SMRC32305

According to Stratistics MRC, the Global Personalized Microbiome Therapeutics Market is accounted for $250 million in 2025 and is expected to reach $1050 million by 2032 growing at a CAGR of 22.7% during the forecast period. Personalized Microbiome Therapeutics are customized treatments designed to modulate an individual's gut, skin, or other microbiomes based on their unique profile. By analyzing microbiota composition and function, therapies are tailored-using probiotics, prebiotics, synbiotics, or microbial consortia-to restore balance, prevent disease, and enhance health outcomes. This precision approach leverages advances in microbiome science, genomics, and AI to enable targeted interventions for digestive, immune, metabolic, and neurological disorders.

According to Cell Press, companies are developing bespoke probiotic consortia, engineered for an individual's gut flora, to treat conditions like IBD more effectively than broad-spectrum alternatives.

Market Dynamics:

Driver:

Rising interest in gut-health therapies

Growing consumer focus on digestive wellness and chronic disease prevention, the demand for gut-health therapeutics is surging globally. Personalized microbiome therapies are gaining traction as precision medicine initiatives emphasize microbiota modulation for metabolic, neurological, and autoimmune disorders. Increasing scientific validation of gut-brain and gut-immune axes further accelerates adoption. Moreover, expanding clinical trial pipelines and collaborations between biotech startups and pharma giants amplify growth. This trend positions microbiome therapeutics as a transformative healthcare frontier.

Restraint:

Complex regulatory approval pathways

The market faces significant hurdles due to stringent regulatory frameworks surrounding live biotherapeutic products and genetic interventions. Approval pathways for microbiome-based drugs remain ambiguous across regions, delaying commercialization. Variations in safety and efficacy standards between regulatory bodies like FDA and EMA add complexity. Additionally, limited clinical evidence and lack of standardized manufacturing protocols slow progression. These barriers elevate development costs and prolong product timelines, restraining market scalability despite strong innovation potential.

Opportunity:

Advancements in microbial gene sequencing

Next-generation sequencing technologies, researchers can now decode individual microbiomes with unprecedented accuracy. This technological evolution enables precision-targeted therapeutic formulations customized to patients' microbial profiles. Growing integration of AI and bioinformatics enhances predictive modeling of microbial behavior. Furthermore, decreasing costs of sequencing expand accessibility for clinical research and diagnostics. Such advancements pave the way for personalized treatment paradigms and broaden the clinical applications of microbiome modulation therapies.

Threat:

Uncertain long-term efficacy data

Despite early clinical promise, limited longitudinal studies challenge the confidence in durable outcomes of microbiome-based treatments. Variability in host response and microbiota stability raises concerns over reproducibility and consistency. Moreover, absence of clear biomarkers for therapeutic success complicates post-treatment evaluation. As competing interventions evolve, skepticism over lasting benefits could slow adoption. Investors and healthcare providers remain cautious until robust, multi-year efficacy data validate clinical dependability and market sustainability.

Covid-19 Impact:

The pandemic underscored the link between immunity and gut health, boosting research in microbiome modulation for immune resilience. However, lockdowns disrupted clinical trials and supply chains for microbial cultures. Post-pandemic recovery reignited interest in probiotic and microbiota-targeted therapies for respiratory and inflammatory conditions. Increased public awareness of personalized health solutions accelerated clinical collaborations. Consequently, COVID-19 served as both a temporary disruptor and a catalyst for microbiome-focused innovation.

The live biotherapeutic products segment is expected to be the largest during the forecast period

The live biotherapeutic products segment is expected to account for the largest market share during the forecast period, due to their direct modulation of host microbiota and proven efficacy in treating recurrent C. difficile, IBD, and metabolic disorders. Products like VOWST and REBYOTA have gained regulatory traction, validating the segment. Their ability to restore microbial balance and deliver targeted benefits makes them ideal for personalized applications. Growing clinical adoption, expanding indications, and robust pipelines position live biotherapeutics as the market's foundational segment.

The rectal & enema delivery segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the rectal & enema delivery segment is predicted to witness the highest growth rate, driven by its superior efficacy in localized gut microbiota restoration. This route bypasses gastric degradation, ensuring higher viability of live microbes. It's particularly effective for lower GI conditions like ulcerative colitis and recurrent C. difficile. Innovations in formulation and patient-friendly devices are improving acceptance. As clinical evidence grows, rectal delivery is gaining favor for precision-targeted microbiome therapies with rapid onset and minimal systemic exposure.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, rising prevalence of GI disorders, and growing interest in preventive health. Countries like China, Japan, and India are investing in microbiome research and personalized medicine. Expanding healthcare infrastructure, supportive regulatory reforms, and increasing consumer awareness of gut health are driving adoption. Local manufacturing capabilities and strategic partnerships further enhance market penetration, making Asia Pacific a key growth region

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR supported by advanced R&D, strong clinical trial infrastructure, and early regulatory approvals. The U.S. leads in microbiome innovation, with robust pipelines, academic collaborations, and venture capital investment. Growing demand for personalized therapies, integration with digital health platforms, and favorable reimbursement policies accelerate adoption. Strategic acquisitions and FDA-approved products like VOWST and REBYOTA reinforce market momentum, positioning North America as the innovation epicenter for microbiome therapeutics

Key players in the market

Some of the key players in Personalized Microbiome Therapeutics Market include Seres Ther, Finch Ther, Ferring Ph, Rebiotix, Synlogic, 4D Pharma, Enterome, Bacthera, Vedanta B, Astellas, BioMe, Nestle He, Takeda, Pfizer, Evelo Bios, Kirin Hold, GSK.

Key Developments:

In October 2025, Seres Therapeutics launched an upgraded version of its microbiome analysis platform, improving the accuracy of predicting patient response to its lead product, SER-109. The update supports real-time strain selection for a next-generation, personalized formulation for recurrent C. difficile infection, enhancing remission rates.

In July 2025, Finch Therapeutics released new data and a corresponding diagnostic algorithm for its CP101 product in recurrent C. difficile, identifying key predictive microbial markers of success. This AI-based tool allows clinicians to stratify patients most likely to benefit, paving the way for a more targeted treatment approach.

In June 2025, Takeda enhanced its "GI-Discover" platform with advanced metagenomic sequencing and machine learning models to identify novel microbiome-derived targets for ulcerative colitis. The update supports faster patient stratification for its clinical trials and the development of companion diagnostics.

Therapy Types Covered:

  • Live Biotherapeutic Products
  • Fecal Microbiota Transplant (FMT)
  • Engineered Probiotics
  • Phage-Based Therapies
  • Postbiotic Formulations
  • Synbiotic Combinations

Route Of Administrations Covered:

  • Oral Capsules
  • Rectal & Enema Delivery
  • Nasal & Inhalation Systems
  • Injectable Formats
  • Transdermal Delivery
  • Encapsulated Microbiome Gels

Technologies Covered:

  • Metagenomics Sequencing
  • AI-Driven Microbiome Mapping
  • CRISPR Gene Editing
  • Single-Cell Analysis
  • Multi-Omics Integration
  • Machine Learning Therapeutic Design

Applications Covered:

  • Gastrointestinal Disorders
  • Metabolic Diseases
  • Neurological Disorders
  • Immune-Related Conditions
  • Cancer Immunotherapy Support
  • Cardiovascular Health

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical Companies
  • Research Laboratories
  • Biotech Startups
  • Contract Manufacturing Organizations
  • Academic Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Microbiome Therapeutics Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Live Biotherapeutic Products
  • 5.3 Fecal Microbiota Transplant (FMT)
  • 5.4 Engineered Probiotics
  • 5.5 Phage-Based Therapies
  • 5.6 Postbiotic Formulations
  • 5.7 Synbiotic Combinations

6 Global Personalized Microbiome Therapeutics Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral Capsules
  • 6.3 Rectal & Enema Delivery
  • 6.4 Nasal & Inhalation Systems
  • 6.5 Injectable Formats
  • 6.6 Transdermal Delivery
  • 6.7 Encapsulated Microbiome Gels

7 Global Personalized Microbiome Therapeutics Market, By Technology

  • 7.1 Introduction
  • 7.2 Metagenomics Sequencing
  • 7.3 AI-Driven Microbiome Mapping
  • 7.4 CRISPR Gene Editing
  • 7.5 Single-Cell Analysis
  • 7.6 Multi-Omics Integration
  • 7.7 Machine Learning Therapeutic Design

8 Global Personalized Microbiome Therapeutics Market, By Application

  • 8.1 Introduction
  • 8.2 Gastrointestinal Disorders
  • 8.3 Metabolic Diseases
  • 8.4 Neurological Disorders
  • 8.5 Immune-Related Conditions
  • 8.6 Cancer Immunotherapy Support
  • 8.7 Cardiovascular Health

9 Global Personalized Microbiome Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Pharmaceutical Companies
  • 9.4 Research Laboratories
  • 9.5 Biotech Startups
  • 9.6 Contract Manufacturing Organizations
  • 9.7 Academic Institutes

10 Global Personalized Microbiome Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Seres Therapeutics
  • 12.2 Finch Therapeutics
  • 12.3 Ferring Pharmaceuticals
  • 12.4 Rebiotix
  • 12.5 Synlogic
  • 12.6 4D Pharma
  • 12.7 Enterome
  • 12.8 Bacthera
  • 12.9 Vedanta Biosciences
  • 12.10 Astellas
  • 12.11 BioMe
  • 12.12 Nestle Health Science
  • 12.13 Takeda
  • 12.14 Pfizer
  • 12.15 Evelo Biosciences
  • 12.16 Kirin Holdings
  • 12.17 GSK

List of Tables

  • Table 1 Global Personalized Microbiome Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Microbiome Therapeutics Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 3 Global Personalized Microbiome Therapeutics Market Outlook, By Live Biotherapeutic Products (2024-2032) ($MN)
  • Table 4 Global Personalized Microbiome Therapeutics Market Outlook, By Fecal Microbiota Transplant (FMT) (2024-2032) ($MN)
  • Table 5 Global Personalized Microbiome Therapeutics Market Outlook, By Engineered Probiotics (2024-2032) ($MN)
  • Table 6 Global Personalized Microbiome Therapeutics Market Outlook, By Phage-Based Therapies (2024-2032) ($MN)
  • Table 7 Global Personalized Microbiome Therapeutics Market Outlook, By Postbiotic Formulations (2024-2032) ($MN)
  • Table 8 Global Personalized Microbiome Therapeutics Market Outlook, By Synbiotic Combinations (2024-2032) ($MN)
  • Table 9 Global Personalized Microbiome Therapeutics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 10 Global Personalized Microbiome Therapeutics Market Outlook, By Oral Capsules (2024-2032) ($MN)
  • Table 11 Global Personalized Microbiome Therapeutics Market Outlook, By Rectal & Enema Delivery (2024-2032) ($MN)
  • Table 12 Global Personalized Microbiome Therapeutics Market Outlook, By Nasal & Inhalation Systems (2024-2032) ($MN)
  • Table 13 Global Personalized Microbiome Therapeutics Market Outlook, By Injectable Formats (2024-2032) ($MN)
  • Table 14 Global Personalized Microbiome Therapeutics Market Outlook, By Transdermal Delivery (2024-2032) ($MN)
  • Table 15 Global Personalized Microbiome Therapeutics Market Outlook, By Encapsulated Microbiome Gels (2024-2032) ($MN)
  • Table 16 Global Personalized Microbiome Therapeutics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 17 Global Personalized Microbiome Therapeutics Market Outlook, By Metagenomics Sequencing (2024-2032) ($MN)
  • Table 18 Global Personalized Microbiome Therapeutics Market Outlook, By AI-Driven Microbiome Mapping (2024-2032) ($MN)
  • Table 19 Global Personalized Microbiome Therapeutics Market Outlook, By CRISPR Gene Editing (2024-2032) ($MN)
  • Table 20 Global Personalized Microbiome Therapeutics Market Outlook, By Single-Cell Analysis (2024-2032) ($MN)
  • Table 21 Global Personalized Microbiome Therapeutics Market Outlook, By Multi-Omics Integration (2024-2032) ($MN)
  • Table 22 Global Personalized Microbiome Therapeutics Market Outlook, By Machine Learning Therapeutic Design (2024-2032) ($MN)
  • Table 23 Global Personalized Microbiome Therapeutics Market Outlook, By Application (2024-2032) ($MN)
  • Table 24 Global Personalized Microbiome Therapeutics Market Outlook, By Gastrointestinal Disorders (2024-2032) ($MN)
  • Table 25 Global Personalized Microbiome Therapeutics Market Outlook, By Metabolic Diseases (2024-2032) ($MN)
  • Table 26 Global Personalized Microbiome Therapeutics Market Outlook, By Neurological Disorders (2024-2032) ($MN)
  • Table 27 Global Personalized Microbiome Therapeutics Market Outlook, By Immune-Related Conditions (2024-2032) ($MN)
  • Table 28 Global Personalized Microbiome Therapeutics Market Outlook, By Cancer Immunotherapy Support (2024-2032) ($MN)
  • Table 29 Global Personalized Microbiome Therapeutics Market Outlook, By Cardiovascular Health (2024-2032) ($MN)
  • Table 30 Global Personalized Microbiome Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Personalized Microbiome Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Personalized Microbiome Therapeutics Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 33 Global Personalized Microbiome Therapeutics Market Outlook, By Research Laboratories (2024-2032) ($MN)
  • Table 34 Global Personalized Microbiome Therapeutics Market Outlook, By Biotech Startups (2024-2032) ($MN)
  • Table 35 Global Personalized Microbiome Therapeutics Market Outlook, By Contract Manufacturing Organizations (2024-2032) ($MN)
  • Table 36 Global Personalized Microbiome Therapeutics Market Outlook, By Academic Institutes (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.